130 related articles for article (PubMed ID: 38084802)
1. Risk of anaphylaxis after COVID-19 vaccination in South Korea: A nationwide self-controlled case series analysis.
Yoon D; Kim JH; Jeong HE; Ko HY; Kim SR; Shin JY;
Allergy; 2024 Mar; 79(3):754-757. PubMed ID: 38084802
[No Abstract] [Full Text] [Related]
2. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021.
Lee E; Lee YK; Kim TE; Hwang I; Jung YH; Lee HR; Song J; Park Y; Cho E; Lee YK
Euro Surveill; 2021 Aug; 26(33):. PubMed ID: 34414880
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study.
Jeong HS; Chun BC
PLoS One; 2024; 19(2):e0297902. PubMed ID: 38381729
[TBL] [Abstract][Full Text] [Related]
4. Safety of BNT162b2 mRNA COVID-19 vaccine in children with chronic kidney disease: a national population study from South Korea.
Choe YJ; Ahn YH; Gwak E; Jo E; Kim J; Choe SA
Pediatr Nephrol; 2024 Feb; 39(2):625-629. PubMed ID: 37880380
[TBL] [Abstract][Full Text] [Related]
5. [Covid-19 vaccination and risk of anaphylaxis - Recommendations for practical management].
Worm M; Ring J; Klimek L; Jakob T; Lange L; Treudler R; Beyer K; Werfel T; Biedermann T; Bircher A; Fischer M; Fuchs T; Heller AR; Hoffmann F; Huttegger I; Kopp MV; Kugler C; Lommatzsch M; Pfaar O; Rietschel E; Rueff F; Schnadt S; Seifert R; Stöcker B; Vogelberg C; Sitter H; Gieler U; Brockow K
MMW Fortschr Med; 2021 Jan; 163(1):48-51. PubMed ID: 33464512
[No Abstract] [Full Text] [Related]
6. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
Lee DS; Kim JW; Lee KL; Jung YJ; Kang HW
Int J Infect Dis; 2022 May; 118():173-182. PubMed ID: 35276381
[TBL] [Abstract][Full Text] [Related]
7. Letter Regarding "Delayed-onset Anaphylaxis After COVID-19 Vaccination".
Mungmunpuntipantip R; Wiwanitkit V
Pediatr Infect Dis J; 2022 Aug; 41(8):e342. PubMed ID: 35476625
[No Abstract] [Full Text] [Related]
8. Adverse reactions to COVID-19 vaccines: A practical approach.
Rutkowski K; Mirakian R; Till S; Rutkowski R; Wagner A
Clin Exp Allergy; 2021 Jun; 51(6):770-777. PubMed ID: 33813758
[TBL] [Abstract][Full Text] [Related]
9. [COVID-19 vaccines increase the risk of anaphylaxis].
Alnæs M; Storaas T; Sørensen M; Stylianou E; Tøndell A
Tidsskr Nor Laegeforen; 2021 Mar; 141(4):. PubMed ID: 33685103
[No Abstract] [Full Text] [Related]
10. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines.
Moghimi SM
Mol Ther; 2021 Mar; 29(3):898-900. PubMed ID: 33571463
[No Abstract] [Full Text] [Related]
11. Delayed-onset Anaphylaxis After mRNA-Based COVID-19 Vaccination in an Adolescent Male.
Shrestha P; Bhattarai S; Dhungana J; Bhattarai T
Pediatr Infect Dis J; 2022 Jun; 41(6):e271. PubMed ID: 35389949
[No Abstract] [Full Text] [Related]
12. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.
Sellaturay P; Nasser S; Islam S; Gurugama P; Ewan PW
Clin Exp Allergy; 2021 Jun; 51(6):861-863. PubMed ID: 33825239
[No Abstract] [Full Text] [Related]
13. Anaphylaxis after COVID-19 vaccination: A registry-based study.
Jaggers J; Samarakoon U; Fu X; Gonzalez-Estrada A; Anvari S; Chong HJ; Van Meerbeke SW; Petrov AA; Chow TG; Banerji A; Judd A; Blumenthal KG
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):3020-3023. PubMed ID: 35964925
[No Abstract] [Full Text] [Related]
14. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines.
Bigini P; Gobbi M; Bonati M; Clavenna A; Zucchetti M; Garattini S; Pasut G
Nat Nanotechnol; 2021 Nov; 16(11):1169-1171. PubMed ID: 34732846
[No Abstract] [Full Text] [Related]
15. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
Peter J
S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
[TBL] [Abstract][Full Text] [Related]
17. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
[TBL] [Abstract][Full Text] [Related]
18. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?
Azenha Rama T; Álvarez-Twose I
J Investig Allergol Clin Immunol; 2021 Apr; 31(2):193-195. PubMed ID: 33574015
[No Abstract] [Full Text] [Related]
19. Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
Maltezou HC; Hatziantoniou S; Theodoridou K; Vasileiou K; Anastassopoulou C; Tsakris A
Vaccine; 2023 Mar; 41(14):2382-2386. PubMed ID: 36872145
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccination-related myocarditis: a Korean nationwide study.
Cho JY; Kim KH; Lee N; Cho SH; Kim SY; Kim EK; Park JH; Choi EY; Choi JO; Park H; Kim HY; Yoon HJ; Ahn Y; Jeong MH; Cho JG
Eur Heart J; 2023 Jun; 44(24):2234-2243. PubMed ID: 37264895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
